Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160329 · ClinicalTrials.gov registry record · Phase 3
Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia
A Phase 3 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00160329: Completed Phase 3 study, sponsored by Stanford University.
NCT00160329 is a Phase 3 study that has completed, run by Stanford University. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00160329, a Phase 3 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The study is looking to compare the impact of lipid levels and HIV viral loads between three different drug regimens: Continuing current regimen (ritonavir boosted regimen), Switching to Atazanavir, or Switching to Atazanavir in combination to Ritonavir.
Interventions
- DRUG Atazanavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160329
The ClinicalTrials.gov registry entry for NCT00160329 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atazanavir is the first listed.
NCT00160329 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00160329 about?
NCT00160329 is a clinical study titled "Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia". The study is looking to compare the impact of lipid levels and HIV viral loads between three different drug regimens: Continuing current regimen (ritonavir boosted regimen), Switching to Atazanavir, or Switching to Atazanavir in combination to Ritonavir.
What is the current status of trial NCT00160329?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2004-01. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00160329?
The interventions under investigation include: Atazanavir (DRUG).
Who is sponsoring clinical trial NCT00160329?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.